
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1118 | 1118 | 1074 | 695 | 849 | - |
Fund Return | 11.84% | 11.84% | 7.36% | -11.41% | -3.22% | - |
Place in category | 77 | 77 | 60 | 101 | 43 | - |
% in Category | 27 | 27 | 24 | 58 | 64 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CIFM China Emerging Power Class A | 5.34B | 5.66 | -5.79 | 7.93 | ||
CIFM China Emerging Power Class H | 5.34B | 5.66 | -5.82 | - | ||
CIFM Technology Qian Yan Alloc | 2.67B | 2.65 | -6.55 | - | ||
China Intl AsiaPacific Advantage St | 2.43B | 2.62 | 2.96 | 4.96 | ||
China International China Advanced | 1.69B | 6.76 | -4.77 | 4.79 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
ICBCCS QY Medical Eq | 10.6B | 6.04 | -9.55 | - | ||
CMF CNI Bio Health Index | 9.81B | 0.43 | -20.62 | - | ||
Hwabao WP CSI Medical Index | 6.3B | 2.89 | -14.65 | - | ||
GF YiLiao BaoJian Eq A | 6.01B | 7.42 | -13.39 | - | ||
ICBCCS MedicalHlth Care Sect Secs I | 2.64B | 8.25 | -8.77 | 5.18 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Jiangsu Hengrui | CNE0000014W7 | 9.15 | 48.90 | +1.31% | |
Kelun Pharm A | CNE100000PW7 | 7.19 | 34.63 | -0.63% | |
Shanghai Allist Pharmaceuticals Co | CNE100005XJ7 | 6.73 | 85.95 | -0.78% | |
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 6.63 | 263.14 | +1.53% | |
WuXi AppTec | CNE1000031K4 | 5.61 | 52.36 | -0.42% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Neutral | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review